MX2019003007A - 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso. - Google Patents
1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso.Info
- Publication number
- MX2019003007A MX2019003007A MX2019003007A MX2019003007A MX2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- substituidas
- carboxamidas
- arilnaftiridin
- Prior art date
Links
- 230000006806 disease prevention Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Braking Arrangements (AREA)
Abstract
La presente solicitud se refiere a nuevas 1-arilnaftiridin-3-carbo xamidas 7-sustituidas, a procesos para su preparación, a su uso, solas o en combinaciones, para el tratamiento y/o prevención de enfermedades y a su uso para la producción de medicamentos para el tratamiento y/o prevención de enfermedades, en particular para el tratamiento y/o la prevención de trastornos cardiovasculares y/o trastornos renales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188728.6A EP3296298A1 (de) | 2016-09-14 | 2016-09-14 | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| EP16202509 | 2016-12-06 | ||
| PCT/EP2017/072339 WO2018050510A1 (de) | 2016-09-14 | 2017-09-06 | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003007A true MX2019003007A (es) | 2019-07-18 |
| MX379715B MX379715B (es) | 2025-03-11 |
Family
ID=59966701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003007A MX379715B (es) | 2016-09-14 | 2017-09-06 | 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso. |
Country Status (40)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3692991A1 (de) | 2015-06-09 | 2020-08-12 | Bayer Pharma Aktiengesellschaft | Positiv allosterische modulatoren des muskarinergen m2 rezeptors |
| WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| JOP20190045A1 (ar) * | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| EP4133101A1 (en) * | 2020-04-08 | 2023-02-15 | Bayer Aktiengesellschaft | Rapid detection of viral infection using rt-pcr |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| JPS60228479A (ja) | 1984-04-26 | 1985-11-13 | Toyama Chem Co Ltd | １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩 |
| DE3508816A1 (de) | 1985-01-10 | 1986-07-10 | Bayer Ag, 5090 Leverkusen | 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren |
| DE3906365A1 (de) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
| DE4301246A1 (de) | 1993-01-19 | 1994-07-21 | Bayer Ag | Chinolon- und Naphthyridoncarbonsäurederivate |
| AU679961B2 (en) * | 1993-08-13 | 1997-07-17 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Novel quinolone carboxylic acid derivatives |
| CA2271136C (en) | 1996-11-28 | 2008-11-25 | Wakunaga Pharmaceutical Co., Ltd. | Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6964966B2 (en) | 2001-04-25 | 2005-11-15 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| WO2003050107A1 (en) | 2001-12-13 | 2003-06-19 | Wockhardt Limited | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| JP2005012561A (ja) | 2003-06-19 | 2005-01-13 | Sony Corp | 画像処理装置、画像処理方法および画像投射装置 |
| EP1650192A4 (en) | 2003-07-24 | 2007-03-21 | Astellas Pharma Inc | QUINOLONE DERIVATIVE OR SALT THEREOF |
| WO2005026165A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| WO2005026145A2 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| DE10343098A1 (de) | 2003-09-18 | 2005-04-14 | Bayer Healthcare Ag | Tetrahydrochinoxaline und ihre Verwendung |
| WO2005049602A1 (en) | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| WO2005056552A1 (en) * | 2003-12-09 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Naphthyridine derivatives and their use as modulators of muscarinic receptors |
| US20090291437A1 (en) * | 2005-11-02 | 2009-11-26 | O'brien Sean | Methods for targeting quadruplex sequences |
| WO2010093341A1 (en) * | 2009-02-10 | 2010-08-19 | Janssen Pharmaceutica N.V. | C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| NZ600674A (en) | 2009-12-17 | 2013-05-31 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
| ES2635340T3 (es) | 2010-02-27 | 2017-10-03 | Bayer Intellectual Property Gmbh | Ariltriazolonas ligadas a bis-arilo y su uso |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PH12013500055A1 (en) | 2010-07-09 | 2017-08-23 | Bayer Ip Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| CN103360388B (zh) | 2012-04-10 | 2017-11-14 | 江苏先声药业有限公司 | 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途 |
| CN102964350A (zh) * | 2012-09-20 | 2013-03-13 | 杨文� | 一种7-六氢吡咯并[1,2-a]吡嗪基喹诺酮羧酸衍生物及其在治疗幽门螺杆菌感染应用 |
| CN103183676B (zh) | 2013-03-12 | 2015-04-08 | 中国医学科学院医药生物技术研究所 | 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用 |
| GB201409044D0 (en) | 2014-05-21 | 2014-07-02 | Ucl Business Plc | New compounds |
| WO2016071212A1 (en) | 2014-11-03 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| CN107406390B (zh) | 2014-11-17 | 2021-04-16 | 奈吉治疗公司 | 单羧酸转运蛋白调节剂及其用途 |
| AU2016276806B9 (en) | 2015-06-09 | 2019-02-21 | Onconic Therapeutics Inc. | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| EP3692991A1 (de) | 2015-06-09 | 2020-08-12 | Bayer Pharma Aktiengesellschaft | Positiv allosterische modulatoren des muskarinergen m2 rezeptors |
| HRP20200064T1 (hr) | 2015-06-09 | 2020-04-03 | Abbvie Inc. | Modulatori nuklearnih receptora (ror) namijenjeni liječenju upalnih i autoimunih bolesti |
| WO2018011017A1 (de) * | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| JOP20190045A1 (ar) * | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
-
2017
- 2017-06-16 JO JOP/2019/0045A patent/JOP20190045A1/ar unknown
- 2017-09-06 CN CN201780056605.4A patent/CN109689656B/zh not_active Expired - Fee Related
- 2017-09-06 LT LTEPPCT/EP2017/072339T patent/LT3512849T/lt unknown
- 2017-09-06 DK DK17772322.8T patent/DK3512849T3/da active
- 2017-09-06 MA MA46235A patent/MA46235B1/fr unknown
- 2017-09-06 CN CN202211273015.6A patent/CN115554294A/zh active Pending
- 2017-09-06 MY MYPI2019001243A patent/MY196473A/en unknown
- 2017-09-06 GE GEAP202115045A patent/GEAP202115045A/en unknown
- 2017-09-06 TN TNP/2019/000083A patent/TN2019000083A1/en unknown
- 2017-09-06 EP EP17772322.8A patent/EP3512849B1/de active Active
- 2017-09-06 AU AU2017326297A patent/AU2017326297B2/en not_active Ceased
- 2017-09-06 HR HRP20211396TT patent/HRP20211396T1/hr unknown
- 2017-09-06 CR CR20190131A patent/CR20190131A/es unknown
- 2017-09-06 JP JP2019535448A patent/JP7295019B2/ja active Active
- 2017-09-06 UA UAA201903730A patent/UA125627C2/uk unknown
- 2017-09-06 US US16/333,079 patent/US10927109B2/en not_active Expired - Fee Related
- 2017-09-06 GE GEAP201715045A patent/GEP20217332B/en unknown
- 2017-09-06 NZ NZ751297A patent/NZ751297A/en not_active IP Right Cessation
- 2017-09-06 HU HUE17772322A patent/HUE056343T2/hu unknown
- 2017-09-06 MX MX2019003007A patent/MX379715B/es unknown
- 2017-09-06 CU CU2019000020A patent/CU24618B1/es unknown
- 2017-09-06 SI SI201730869T patent/SI3512849T1/sl unknown
- 2017-09-06 WO PCT/EP2017/072339 patent/WO2018050510A1/de not_active Ceased
- 2017-09-06 CA CA3036497A patent/CA3036497A1/en active Pending
- 2017-09-06 SG SG11201901973RA patent/SG11201901973RA/en unknown
- 2017-09-06 ES ES17772322T patent/ES2887674T3/es active Active
- 2017-09-06 KR KR1020237006804A patent/KR20230035437A/ko not_active Abandoned
- 2017-09-06 CN CN202211273380.7A patent/CN115429798A/zh active Pending
- 2017-09-06 BR BR112019004982A patent/BR112019004982A2/pt not_active IP Right Cessation
- 2017-09-06 PL PL17772322T patent/PL3512849T3/pl unknown
- 2017-09-06 KR KR1020197007039A patent/KR20190046851A/ko not_active Withdrawn
- 2017-09-06 RS RS20211093A patent/RS62299B1/sr unknown
- 2017-09-06 PE PE2019000524A patent/PE20190803A1/es unknown
- 2017-09-06 CN CN202211273001.4A patent/CN115477649A/zh active Pending
- 2017-09-14 UY UY0001037403A patent/UY37403A/es unknown
- 2017-09-14 TW TW106131572A patent/TWI758325B/zh not_active IP Right Cessation
-
2019
- 2019-02-28 IL IL265106A patent/IL265106B/en unknown
- 2019-03-12 PH PH12019500535A patent/PH12019500535A1/en unknown
- 2019-03-14 CO CONC2019/0002361A patent/CO2019002361A2/es unknown
- 2019-03-14 DO DO2019000060A patent/DOP2019000060A/es unknown
- 2019-03-14 CL CL2019000670A patent/CL2019000670A1/es unknown
- 2019-03-14 NI NI201900023A patent/NI201900023A/es unknown
- 2019-03-14 EC ECSENADI201918116A patent/ECSP19018116A/es unknown
- 2019-04-12 ZA ZA2019/02325A patent/ZA201902325B/en unknown
-
2021
- 2021-01-28 US US17/161,186 patent/US20220089591A1/en not_active Abandoned
- 2021-01-28 US US17/161,201 patent/US11472803B2/en active Active
- 2021-09-02 CY CY20211100782T patent/CY1124492T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| DOP2015000185A (es) | Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos | |
| ECSP14013224A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| CU20140082A7 (es) | Pirimidinas y triazinas fusionadas sustituidas y sus uso | |
| UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
| GT201600002A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| MX383715B (es) | Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas. | |
| ECSP17081322A (es) | Moduladores alostéricos positivos del receptor muscarínico m2 | |
| UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| SV2018005783A (es) | 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas su uso | |
| NI201900023A (es) | 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
| CO2019011227A2 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
| MX2016000037A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| CO2019011285A2 (es) | N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso | |
| DOP2015000290A (es) | Benzoxazoles sustituidos | |
| MX376504B (es) | Composiciones para el tratamiento de enfermedades renales y/o hepaticas. | |
| CR20120445A (es) | Ariltriazolonas ligadas a bisarilo y su uso |